Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Phone app and edible tags aim to boost HIV pill adherence

NCT ID NCT06465862

Knowledge-focused Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to test a new system that uses tiny silica particles on HIV medication (Biktarvy) and a smartphone app to help people track whether they have taken their pills. The goal was to see if the system is easy to use and accurate over 90 days. However, the study was withdrawn before any participants were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Biktarvy (antiretroviral pill) tagged with silica microparticles
What this could lead to
If successful, this system could provide a simple way for people with HIV to track their daily medication using a smartphone, potentially improving adherence and health outcomes.
What could go wrong
The study was withdrawn before enrolling any participants, so no data were collected. The technology depends on specific phone models and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Expected to start

Sep 2024

An estimate. Start dates often move.

Expected to finish

Apr 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 or older 2. Living with HIV 3. Currently prescribed and taking Biktarvy as ART for at least 3 months 4. Undetectable viral load in prior 6 months 5. Owns iPhone model 11 or higher (non-SE only) Exclusion Criteria: 1. Not English-speaking 2. Unwilling to interact with the TruTag app

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Compliance, medication are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease Medication Adherence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Compliance, medication HIV Medication adherence

More trials for these conditions

Other studies related to the condition(s) this trial covers.